Cameron Hurst Edwards Lifesciences Corp EW-N TOP PICK Feb 08, 2018

Trans-catheter aortic valve replacement is their business, a best in class valve that's been taken up widely in hospitals around the world. This market will double in three years, and they are the big player. (Analysts' target of $142.80)

When it came down to his model price it was the only buying opportunity there was in the last eight years. He loves the company. Model price is $99.94, a 30% premium that it is trading at. He can only wish for a pull back.

He has owned IRTC-O in the past. It is in the medical device space and has equipment that looks for heart arrhythmia and loads the data to the cloud. The market has not yet said this stock has taken a positive turn yet. Earnings are growing and it is growing into its share price. He wants to see it break above $85-$87 before getting back in. He would prefer holding EW-N

Reported a solid quarter and guidance in last April. Is up 20% YTD, but has more room to run. He's bullish medical devices.

That had a terrible quarter. They must do better.

The interesting is that it's still at 25x post-drop. You're seeing earnings misses get punished because the aggregate multiple they trade at is still on the high end.